Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock $0.0001 par value per share
-
Shares outstanding
-
16.5M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
13.6M
-
Shares change
-
-2M
-
Total reported value, excl. options
-
$351M
-
Value change
-
+$19.2M
-
Put/Call ratio
-
0.03
-
Number of buys
-
33
-
Number of sells
-
-24
-
Price
-
$25.79
Significant Holders of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) as of Q3 2025
73 filings reported holding RAPT - RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share as of Q3 2025.
RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.6M shares
of 16.5M outstanding shares and own 82.4% of the company stock.
Largest 10 shareholders include TCG Crossover Management, LLC (1.64M shares), Foresite Capital Management VI LLC (1.56M shares), RTW INVESTMENTS, LP (1.47M shares), ORBIMED ADVISORS LLC (1.09M shares), BOONE CAPITAL MANAGEMENT LLC (782K shares), Deep Track Capital, LP (751K shares), VANGUARD GROUP INC (696K shares), Nantahala Capital Management, LLC (623K shares), Ikarian Capital, LLC (615K shares), and Siren, L.L.C. (580K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.